Research
Lack of neo-sensitization to Pen a 1 in patients treated with mite sublingual immunotherapy
-
* Corresponding author: Renato E Rossi immunoway@libero.it
1 Allergy Unit, National Health Service, Rete di Allergologia Regione Piemonte, Cuneo 1, Italy
2 Dipartimento di Analisi Chimico-Cliniche e Microbiologia, Ospedali di Fossano e Savigliano, Italy
3 Allergy/Pulmonary rehabilitation, ICP Hospital, Milan, Italy
4 Research and Development, Stallergènes SA, Antony, France
5 Medical and Scientific Department, Stallergenes, Milan, Italy
6 Allergy and Respiratory Diseases DIMI, University of Genoa Italy
7 Laboratorio Centrale di Analisi, Istituto Gaslini, Genoa, Italy
Clinical and Molecular Allergy 2010, 8:4 doi:10.1186/1476-7961-8-4
Published: 15 March 2010Abstract
Background
Some studies reported the possible induction of food allergy, caused by neo-sensitization to cross-reacting allergens, during immunotherapy with aeroallergens, while other studies ruled out such possibility.
Objectives
The aim of this study was to evaluate the development of neo-sensitization to Pen a 1 (tropomyosin) as well as the appearance of reactions after ingestion of foods containing tropomyosin as a consequence of sublingual mite immunization.
Materials and methods
Specific IgE to Tropomyosin (rPen a 1) before and after mite sublingual immunotherapy in 134 subjects were measured. IgE-specific antibodies for mite extract and recombinant allergen Pen a 1 were evaluated using the immunoenzymatic CAP system (Phadia Diagnostics, Milan, Italy).
Results
All patients had rPen a 1 IgE negative results before and after mite SLIT and did not show positive shrimp extract skin reactivity and serological rPen a 1 IgE conversion after treatment. More important, no patient showed systemic reactions to crustacean ingestion.
Conclusions
Patients did not show neo-sensitization to tropomyosin, a component of the extract (namely mite group 10) administered. An assessment of a patient's possible pre-existing sensitisation to tropomyosin by skin test and/or specific IgE prior to start mite extract immunotherapy is recommended.
Trial Registration
This trial is registered in EudraCT, with the ID number of 2010-02035531.